Dr Reddy's Partners with Alvotech to Expand in Oncology Biosimilars

• Dr Reddy’s partners with Alvotech to develop a Keytruda biosimilar

• The biosimilar targets the multi-billion-dollar global oncology market

• The alliance aims to improve global access to affordable cancer therapies

Dr Reddy's Laboratories has made a strategic partnership with global biotechnology company Alvotech for the co-development and commercialization of a biosimilar of Keytruda (pembrolizumab)—the market-leading immunotherapy in multiple cancer indications.

On Thursday, the city-pharma major made a statement in which it said that the co-development agreement entails manufacturing and global commercialization commitments of the biosimilar medicine. The alliance is with an aim to tap the oncology space, which is worth multibillions, with Keytruda recording US dollar 29.5 billion in global revenues in 2024.

Dr Reddy's CEO, Erez Israeli, said, "This partnership enhances our oncology pipeline, with pembrolizumab being one of the most urgent treatments in immuno-oncology, and it also demonstrates our dedication to making advanced treatments accessible to more patients globally."

Dr Reddy's and Alvotech will share development and manufacturing responsibilities under the deal, and except in a handful of countries, will maintain worldwide rights to market the product independently.

Also Read: BioNTech, BMS Partner to Advance BNT327 in Solid Tumor Cancers

Robert Wessman, Alvotech's CEO and Chairman, quoted "This transaction highlights our R&D and biosimilar production capabilities. Collectively, we will make life-saving biologics more affordable and accessible to patients around the globe earlier."

The partnership is anticipated to accelerate development cycles and further secure the worldwide potential of this biosimilar candidate, which responds to the increasing need for cost-effective oncology treatments.